RxDoctor Payments Data

Dale Menard, MD

Neurology · Hickory, NCNPI 1629031323

Payments from drug & device makers

$7,897in general payments, 2019–2025

Across 329 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Teva Pharmaceuticals USA, Inc.$958
  • AbbVie$807
  • Pfizer$523
  • Novartis$248
  • UCB, Inc.$174
  • plus $2K from 48 others

What the payments were for

  • Speaking & faculty fees$220%
  • Food & beverage$5,16898%
  • Education$1082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,897 in reported general payments places this provider in the 65th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$131,719
Medicare patients
569
Services billed
2,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyremSodium Oxybate27$550,080
EpidiolexCannabidiol (Cbd)21$222,038
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$190,073
Kesimpta PenOfatumumab20$189,834
Aimovig AutoinjectorErenumab-Aooe168$178,286
AustedoDeutetrabenazine11$151,286
Nurtec OdtRimegepant Sulfate91$114,761
LamictalLamotrigine45$70,221
AptiomEslicarbazepine Acetate26$63,307
KeppraLevetiracetam20$55,955
NeuproRotigotine23$48,540
UbrelvyUbrogepant39$42,341
TopamaxTopiramate25$37,461
Keppra XrLevetiracetam27$34,256
QuliptaAtogepant16$31,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$12$190,07313 claims
Teva Pharmaceuticals USA, Inc.Austedo$958$151,28611 claims
PfizerNurtec Odt$523$114,76191 claims
AbbVieUbrelvy, Qulipta$807$73,74255 claims
GSKLamictal$12$70,22145 claims
Sunovion Pharmaceuticals Inc.Aptiom$81$63,30726 claims
UCB, Inc.Neupro$174$48,54023 claims
Lundbeck LLCOnfi$48$20,66612 claims
Upsher-smith Laboratories LLCTopiramate$18$4,993431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 566 neurology providers in North Carolina.

Other neurology in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →